Recursion Pharmaceuticals, Inc. income statement

In fiscal 2025, Recursion Pharmaceuticals, Inc. reported revenue of $74.7m, up 26.9% on the year before, operating income of −$648m (a -867.9% margin) and net income of −$645m, or −$1.44 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Recursion Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	2	4	10	40	45	59	75	68
Cost of revenue	—	0	0	48	43	45	71	48
Gross profit	—	4	10	−8	2	14	4	20
Research and development	46	63	135	156	241	314	475	373
General and administrative	19	25	58	82	111	178	177	142
Operating income	−62	−85	−183	−246	−350	−479	−648	−495
Interest expense	1	1	3	0	0	2	2	1
Income before tax	—	—	−186	−239	−332	−465	−645	−480
Income tax	0	0	0	0	−4	−1	−0	−5
Net income	−62	−87	−186	−239	−328	−464	−645	−476
Diluted EPS	−$2.87	−$3.99	−$1.49	−$1.36	−$1.58	−$1.69	−$1.44	−$0.89
Diluted shares (average)	22m	22m	125m	176m	208m	274m	447m	532m
EBITDA	−60	−81	−174	−234	−326	−443	−564	−421

US$ millions unless shown otherwise. Fiscal quarters.

Recursion Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	5	15	19	5	36	6	8	19
Cost of revenue	13	22	20	15	14	12	11	10
Gross profit	−8	−7	−1	−10	21	−6	−4	9
Research and development	98	130	129	121	96	88	90	99
General and administrative	77	55	47	42	34	35	42	33
Operating income	−184	−191	−176	−172	−108	−129	−135	−123
Interest expense	1	1	0	1	−0	0	0	0
Income before tax	−179	−203	−172	−162	−108	−122	−131	−119
Income tax	0	−0	0	0	0	−5	−0	0
Net income	−179	−202	−172	−162	−108	−118	−131	−119
Diluted EPS	−$0.57	−$0.50	−$0.41	−$0.36	−$0.17	−$0.22	−$0.25	−$0.22
EBITDA	−171	−172	−152	−151	−89	−109	−117	−107

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CYTK vs RXRX ABCL vs RXRX RXRX vs WVE RXRX vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Recursion Pharmaceuticals, Inc.